Increlex (mecasermin, recombinant, rh-IGF-1) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

	URGENT			
MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIG	HT (LB/KG): ALLERGIES:			

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Increlex (mecasermin, recombinant, rh-IGF-1) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:		
PRIOR AUTHORIZATION.	ode(s):	ICD-10:		
Clinical Information: Is Increlex being prescribed by an end	ocrinologist? 🗆 Yes 🗆 No			
 Does the patient have normal to elevated grow th hormone levels?* Yes No (Please provide chart documentation.) Does the patient have a grow th hormone gene deletion and has the patient developed neutralizing antibodies to growth hormone?* Yes No (Please provide chart documentation.) Does the patient have a height standard deviation score of negative 3.0 or less prior to starting treatment?* Yes No (Please provide chart documentation.) Does the patient have a basal IGF-1 standard deviation score of negative 3.0 or less prior to starting treatment?* Yes No (Please provide chart documentation.) 				
Are the patient's epiphyses closed?* Yes No Please provide chart documentation (i.e., chart notes) supporting this information.				
Does the patient have an active or suspected malignancy? □ Yes □ No (Please provide chart documentation.)				
Reauthorization: If this is a reauthorization request, also answer the following question: Has there been an objective response to therapy, defined as a minimum grow th rate of at least 2 cm/year?* Yes No *Please provide chart documentation (i.e., chart notes) supporting this information.				
Are there any other comments, diagnorphysician feels is important to this rev	oses, symptoms, medications tried or fa riew?	iled, and/or any other information the		



Increlex (mecasermin, recombinant, rh-IGF-1) **Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811



Revision Date: 08/22/2018